Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for Autologous Stem Cell Transplantation (ASCT): Alcyone-optimized Real World Evidence (RWE) Data
Sponsor: Adknoma Health Research
A observational or N/A phase clinical study on Multiple Myeloma and Non-eligible for Autologous Stem Cell Transplantation (ASCT), this trial is ongoing. The trial is conducted by Adknoma Health Research and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2025 — Dec 2025 [monthly]
Recruiting
-
Sep 2024 — Sep 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Sep 2022 — Jul 2024 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Recruiting
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adknoma Health Research
- Janssen, LP
- PETHEMA Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arganda, Spain , Barcelona, Spain , Granada, Spain , Jaén, Spain , Las Palmas de Gran Canaria, Spain , León, Spain , Madrid, Spain , Murcia, Spain , Ourense, Spain , Oviedo, Spain and 15 more locations